Novo Nordisk Should Have Studied Insulin Icodec Twice-Weekly Dosing, US Panel Says

Complexity
Novo Nordisk said a twice-weekly insulin icodec regimen would have created too much complexity. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers